Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the U.S. Food and Drug...
Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence
Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced today that it has received clinical trial...
RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
Shenzhen RaysightMed Co., Ltd. (“RaysightMed”) announced today the successful completion of a strategic financing round...
CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
CSPC Innovation Pharmaceutical Co., Ltd. (SHE: 300765) announced today the initiation and public registration of...
Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks
Sanofi S.A. (NASDAQ: SNY) announced today positive top-line results from the Baby-COMET Phase 3 study...
BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced today positive top-line results from...
Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced today that it has entered into...
METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
METiS TechBio (HKG: 7666) announced an exclusive global licensing agreement with Boulevard Bio, a U.S....
Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
Eli Lilly (NYSE: LLY) and Innovent Biologics (HKG: 1801) announced a strategic collaboration granting Innovent...
Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its wholly-owned subsidiary Qyuns Safe Biology Medicine...
Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) announced that the National Medical Products Administration (NMPA)...
Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Anhui Wanbang Pharmaceutical Technology Co., Ltd. (SHE: 301520) announced it will acquire a 75.52% equity...
AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx
AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, demonstrating...
Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced the commercial launch of AXELIOS 1, its...
Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients
Merck & Co., Inc. (MSD; NYSE: MRK) announced a strategic agreement with the ADAP Crisis...
Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline
Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) and Kartos Therapeutics announced a definitive merger agreement under...
Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed – RenNano Platform Cleared of Antibody Technology Violations
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced it has received a favorable...
Innovative Medical Management Subsidiary Cereblink Secures Registration for AM5 Upper Limb Rehabilitation Exoskeleton – EMG-Driven System Targets CNS Injury Recovery
Innovative Medical Management Co., Ltd. (SHE: 002173) announced that its holding subsidiary Cereblink (Hangzhou) Technology...
Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories
Hua Medicine (HKG: 2552) announced that the Pharmaceutical Administration Bureau of the Macau Special Administrative...
AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older
AbbVie (NYSE: ABBV) announced on June 26, 2026, that the U.S. Food and Drug Administration...